Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
Two novel side chains which had previously been found to enhance antagonist activity in the dihydrobenzoxathiin SERM series were applied to three existing platforms. The novel side chains did not improve the antagonist activity of the existing platforms.
Blizzard
Timothy A
TA
Merck Research Laboratories, RY800-B116, PO Box 2000, Rahway, NJ 07065, USA. tim_blizzard@merck.com
Morgan
Jerry D
JD
Chan
Wanda
W
Birzin
Elizabeth T
ET
Pai
Lee-Yuh
LY
Hayes
Edward C
EC
DaSilva
Carolyn A
CA
Mosley
Ralph T
RT
Yang
Yi Tien
YT
Rohrer
Susan P
SP
Dininno
Frank
F
Hammond
Milton L
ML
D000818:Animals; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors*; D008024:Ligands; D010075:Oxathiins / Q000737:chemistry*; D051381:Rats; D020845:Selective Estrogen Receptor Modulators / Q000737:chemistry* / Q000494:pharmacology*
D047628:Estrogen Receptor alpha; D008024:Ligands; D010075:Oxathiins; D020845:Selective Estrogen Receptor Modulators; C500019:dihydrobenzoxathiin